The burden of psoriasis is not determined by disease severity only

被引:113
作者
Heydendael, VMR
de Borgie, CAJM
Spuls, PI
Bossuyt, PMM
Bos, JD
de Rie, MA
机构
[1] Univ Amsterdam, Dept Dermatol, Acad Med Ctr, NL-1100 DD Amsterdam, Netherlands
[2] Univ Amsterdam, Dept Clin Epidemiol & Biostat, Acad Med Ctr, NL-1100 DD Amsterdam, Netherlands
关键词
SF-36; PASI; quality of life;
D O I
10.1111/j.1087-0024.2004.09115.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 [皮肤病与性病学];
摘要
Psoriasis is a chronic scaling and inflammatory skin disease that can affect patients' quality of life and daily functioning. We studied the scores of 85 patients suffering from moderate to severe plaque-type psoriasis, participating in a randomized controlled trial. We compared their scores on a generic quality-of-life instrument with data from two reference populations. We examined associations between clinical severity, as measured by the components of the Psoriasis Area and Severity Index (PASI), and the respective quality-of-life subdimensions, measured by the Medical Outcome Survey Short Form 36 (SF-36), to find out what elements of disease activity are related with impaired quality of life. Compared to the reference population, quality of life was impaired in terms of bodily pain and social functioning. There were no significant correlations between overall disease severity, as measured by PASI, and the SF-36 subdimensions. When examining the PASI components, we found significant correlations between desquamation on the upper limbs and mental health and bodily pain (r = -0.23 and r = -0.28, respectively) and between desquamation on the scalp and mental health (r = -0.29). In conclusion, we found that psoriasis patients had a lower quality of life than a reference population, without a significant relation between disease severity or disease area and quality of life. Yet psoriasis lesions located on visible body parts are significantly correlated with aspects of quality of life.
引用
收藏
页码:131 / 135
页数:5
相关论文
共 17 条
[1]
Translation, validation, and norming of the Dutch language version of the SF-36 Health Survey in community and chronic disease populations [J].
Aaronson, NK ;
Muller, M ;
Cohen, PDA ;
Essink-Bot, ML ;
Fekkes, M ;
Sanderman, R ;
Sprangers, MAG ;
Velde, AT ;
Verrips, E .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1998, 51 (11) :1055-1068
[2]
Convergent and discriminant validity of a generic and a disease-specific instrument to measure quality of life patients with skin disease [J].
Chren, MM ;
Lasek, RJ ;
Quinn, LM ;
Covinsky, KE .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1997, 108 (01) :103-107
[3]
The suitability of quality-of-life questionnaires for psoriasis research - A systematic literature review [J].
de Korte, J ;
Mombers, FMC ;
Sprangers, MAG ;
Bos, JD .
ARCHIVES OF DERMATOLOGY, 2002, 138 (09) :1221-1227
[4]
FINLAY AY, 1995, BRIT J DERMATOL, V132, P236
[5]
Fortune DG, 1997, BRIT J DERMATOL, V137, P755
[6]
SEVERE PSORIASIS - ORAL THERAPY WITH A NEW RETINOID [J].
FREDRIKSSON, T ;
PETTERSSON, U .
DERMATOLOGICA, 1978, 157 (04) :238-244
[7]
Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis [J].
Heydendael, VMR ;
Spuls, PI ;
Opmeer, BC ;
de Borgie, CAJM ;
Reitsma, JB ;
Goldschmidt, WFM ;
Bossuyt, PMM ;
Bos, JD ;
de Rie, MA .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (07) :658-665
[8]
THE PSORIASIS DISABILITY INDEX - FURTHER ANALYSES [J].
KENT, G ;
ALABADIE, M .
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 1993, 18 (05) :414-416
[9]
Krueger G, 2001, ARCH DERMATOL, V137, P280
[10]
Interpersonal concerns and psychological difficulties of psoriasis patients: Effects of disease severity and fear of negative evaluation [J].
Leary, MR ;
Rapp, SR ;
Herbst, KC ;
Exum, ML ;
Feldman, SR .
HEALTH PSYCHOLOGY, 1998, 17 (06) :530-536